News and information for patients.
From JD Faccinetti, co-founder and chief editor – I like to ramble, so here it goes. I was musing about how unique and essential this little gland is—the size of a pea, the pituitary runs almost
With the upcoming WAPO Summit slated for this October 3, we thought we’d give our audience around the world more information about the Summit and the organization itself. This podcast will give you a rundown
From the desk of J D Faccinetti, co-founder – I was first seriously exposed to mindfulness a few years ago when an expert on the subject made a remarkable presentation at an international conference in Italy.
From Risa Heidt, triathlete, ironwoman – Marshmallow Clouds – It was September 2018. In preparation for my next big cycling event, a 100-mile Century ride in New Mexico, I rode 50 miles a day for weeks
Acromegaly patients and healthcare providers worldwide can participate in this survey designed to provide information that may help improve quality of life during the COVID-19 pandemic. Much of this initiative’s success will depend on your
From Leslie Edwin, President of CSRF and PWN Contributor – On June 18, 2020, online medical journal The Lancet Diabetes and Endocrinology published a report about the association between high cortisol and death rate with COVID-19.
On June 7th the patient support and advocacy group Acromegaly Community hosted another online presentation in its series, “Education by the Experts”. Linda M. Rio, a frequent contributor to PWN, was featured at the Acromegaly Community’s
If you’d like to learn more about Addison’s disease, here’s a perfect opportunity to do so. The Advanced Practice in Endocrinology Nursing is a comprehensive resource on Adrenal Insufficiency and three chapters from the book are
From the editors’ desk – A recent Endocrine Web article by Kimberly B. Bjugstad Ph.D. highlights a new oral octreotide drug for Acromegaly. The drug currently is on an FDA Phase III trial, referred to as OPTIMAL,
This is a series of urgent clinical guidance documents on the management of endocrine conditions in the time of COVID-19. This clinical guidance document underwent expedited open peer review by Jérôme Bertherat (Paris, France), André
In this podcast, Dr. Lewis Blevins discusses a new drug for Cushing’s disease recently approved in the US.
Recordati Rare Diseases, Inc., based in Lebanon, NJ, has recently acquired the rights to SIGNIFOR® LAR and the FDA approval for ISTURISA®(osilodrostat). Both products treat pituitary diseases. SIGNIFOR LAR, a “2nd generation” somatostatin analog given
From the desk of J D Faccinetti Chairman, CEO and chief editor Pituitary World News. We recently published two COVID-19 related articles that focused on subjects that are very much in everyone’s mind. One was